Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21772273 | 0.82 | KDM4E (0.38) | KDM4EALDH1A1MAPTKMT2APIK3CD | |
| SCHEMBL20745279 | 0.80 | PIK3CD (0.48) | KDM4EALDH1A1MAPTKMT2APIK3CD | |
| SCHEMBL24505430 | 0.76 | CHRNB2 (0.41) | MAPTKMT2A | |
| SCHEMBL3315860 | 0.75 | KDM4E (0.33) | KDM4EALDH1A1PIK3CD | |
| SCHEMBL3127669 | 0.74 | AVPR1A (0.34) | KMT2A | |
| SCHEMBL3723198 | 0.74 | PIK3CD (0.38) | PIK3CD | |
| SCHEMBL6738562 | 0.72 | CHRNB2 (0.44) | — | |
| SCHEMBL2333679 | 0.71 | — | — | |
| SCHEMBL3728955 | 0.70 | — | — | |
| SCHEMBL24975368 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010049731-A1 | PYRAZOLO- AND IMIDAZOPYRIDINYLPYRIMIDINEAMINES AS IGF-1R TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | KDM4E 2169/4885ALDH1A1 649/4885MAPT 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.